Dr. Dalia Megiddo managed 2 venture capital funds: 7 Health Ventures (2006-2010) and InnoMed Ventures, since 2000. She is the founder of multiple BioPharma and Medtech companies among others- Chiasma ( NASDAQ -CHMA ) Alcobra (NASDAQ- ADHD) Bioblast (NASDAQ- ORPN) and Medingo (Sold to Roche).
Dr. Megiddo has been involved in the Life Science Venture Capital Industry since 1999 and is well recognized as one of the leaders in the healthcare investment community both in Israel and internationally. She is a frequent speaker at local and international meetings and served as a board member at Given Imaging (NASDAQ-GIVN) Elron (NASDAQ- ELRN) Alcobra (NASDAQ- ADHD) and Bioblast (NASDAQ- ORPN) and Foamix (NASDAQ-FOMX). Dr. Megiddo is member of the scientific-investment advisory boards to several academic institutes in Israel including the Technion.

Dr. Megiddo holds an MBA from Kellogg- Recanati School of Business , and teaches at various entrepreneurial programs in Israeli universities. She completed her medical studies at the Hebrew University’s Hadassah Medical School and a specialty program in Family Medicine.

After spending a few years as a faculty member in the Family Medicine department at the Hebrew University in Jerusalem, Dr. Megiddo founded and sold two successful businesses in the medical field: The Journal Club – Israel’s leading provider of Continuing Medical Education for physicians, and Academia Medica – a medical multimedia developer and worldwide distributor for Continuing Medical Education programs for physicians.